CN106267315B - A kind of wound repair dressing - Google Patents

A kind of wound repair dressing Download PDF

Info

Publication number
CN106267315B
CN106267315B CN201610665179.1A CN201610665179A CN106267315B CN 106267315 B CN106267315 B CN 106267315B CN 201610665179 A CN201610665179 A CN 201610665179A CN 106267315 B CN106267315 B CN 106267315B
Authority
CN
China
Prior art keywords
fiber
collagen
porous
sill
carried out
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610665179.1A
Other languages
Chinese (zh)
Other versions
CN106267315A (en
Inventor
朱坤福
祝蕾
赵忠军
张天奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANDONG ZHUSHI PHARMACEUTICAL GROUP CO., LTD.
Original Assignee
Shandong Zhushi Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Zhushi Pharmaceutical Group Co Ltd filed Critical Shandong Zhushi Pharmaceutical Group Co Ltd
Priority to CN201610665179.1A priority Critical patent/CN106267315B/en
Publication of CN106267315A publication Critical patent/CN106267315A/en
Application granted granted Critical
Publication of CN106267315B publication Critical patent/CN106267315B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/425Porous materials, e.g. foams or sponges
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A61L15/325Collagen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/44Medicaments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412Tissue-regenerating or healing or proliferative agents
    • A61L2300/414Growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Materials For Medical Uses (AREA)

Abstract

A kind of wound repair dressing is porous material, is characterized in that, surface is attached with the collagen of Porcine HGF.

Description

A kind of wound repair dressing
Technical field
The present invention relates to a kind of wound repair dressing, belong to medical aid field.
Background technique
The surface of a wound is normal skin (tissue) causes injury the factor such as surgical operation, external force, heat, electric current, chemical substance, low in the external world Damage caused by under the effects of temperature and body internal factor such as local blood supply obstacle.It is often accompanied by the broken of skin integrity The loss of bad and a certain amount of normal tissue, meanwhile, the normal function of skin is impaired.Also referred to as wound or wound.The surface of a wound is repaired Multiple both wound reparations.Wound repair is most important, the most basic problem that wound, burns unit or even entire medical field are faced One of, but it is really carried out system and in-depth study as an independent project, recent 20 years just cause people The attention of height.On the one hand, many basic problems of wound repair are on the other hand, modern in the past there is no really achieving a solution The development of medicine, especially molecular biology proposes many new problems or even some important concepts to wound repair again Also in continuous update and development.If traditional dressing (gauze) only plays simple flap coverage, and it is present, develop dressing Concept basic variation has had occurred, i.e. flap coverage is not only wanted in dressing, should also have the function of promoting tissue repair, i.e. institute It calls " active dressing " or " revolutionary dressing ".Secondly, the requirement with the increasingly improvement of living standards of the people, to quality of life It is higher and higher, thus the chronic skin ulcer less paid attention in the past for people is also increasingly paid attention to by people with scar prevention. Therefore, further pay attention to wound repair research be both after learned needs and social development to certain phase to medicine and The new demand that biology proposes.
Foreign countries attach great importance to wound repair, and basic research has been goed deep into cell, molecule and gene level.The seventies with Come, due to can effectively obtain large amount of cell factor and for zoopery, so that with growth factor and wound repair relationship It walks for the tissue repair research foreign countries of breach in forefront, and has thus driven the development of entire wound repair.By nearly 20 Year effort, the cytology of tissue repair, extracellular matrix and collagenic supersession, growth factor promote (suppression) wound repair mechanism, Chronic refractory pathophysiological features and the promoting healing method for closing ulcer, the origin cause of formation of hyperplastic scar and control, active dressing are ground System and gene therapy etc. achieve the progress to attract people's attention, and many Basic Research Results have started to be applied to clinic.
We are continued for constantly in the national research in relation to wound repair, and obtain in fields such as burn wound reparations Encouraging success.But generally, holistic approach of the China in this field still lags behind western developed country, and basic research is fallen again Afterwards in clinical treatment.Since wound repair is a system engineering, it is related to many medicine necks such as surgery, traumatology department, burn, shaping Domain, and with biochemistry, biology, molecular biology, biomethanics and biomaterial etc. it is many basis and applied science There is extensive connection.Therefore, if its project great as one is not carried out interdisciplinary, multi-disciplinary tackling key problem, it is clear that It is difficult to make a breakthrough.It is large quantities of that the famous academician of the Chinese Academy of Engineering Sheng Zhi in China is bravely taught, 304 hospital of Beijing pays professor dogface etc. Medicine celebrity began to deliver a large amount of papers or monograph successively early in 2003, and proposed and " to make full use of the modern times The achievement of High biotechnology is explored the normally secret with tissue repair generation out of control from cell, molecule and gene level, is found It is reliable to promote restorative procedure, accelerate the exploitation and application of new product." viewpoint.Currently, Commercialization application is in clinic Skin wound covering has: epidermal sheet, acellular dermal matrix, collagen sponge membrane, collagen gel film etc..1. epidermis Cell patch: diaphragm (KC) disadvantage is that the skin biopsy sample of patient must be taken, needs 2-3 weeks time, lack Dermal components, diaphragm belittle frangible [O ' ConnerNE, Malliken JB, Bankaclilegcls, et al.Grafting of burns with cultured epitheliunt prepared from autologous epidermal cells[J] .Lancet, 1981,1:75-78].2. acellular dermal matrix: the disadvantage is that un-cleared antigenic substance may be contained, there is biography It catches an illness the danger of poison, and material hole connectivity is poor.3. collagen sponge membrane: such as 94118836.1 He of Chinese patent 01134743.0, the disadvantage is that the raw sub- factor of cell is not contained in material, and poor mechanical property, it cannot be anti-infective;It is Chinese special Sharp 200510022581.X does not introduce microsphere sustained-release technology although being directly added into growth factor in material, and growth factor is easy Lose bioactivity.4. collagen gel: such as Chinese patent CN02117585.3 and CN03130382.X, the disadvantage is that production process Complexity, collagen gel can shrink 80% or so, and resistance degraded by collagenase ability is poor, is subject to virus infection and immunological rejection is anti- It answers, brittleness is big, and surgical procedure is difficult.
Summary of the invention
The present invention provide in view of the deficiencies of the prior art it is a kind of it is extremely low with no immunological rejection or immunological rejection effect, answer With in extensive range, wound repair excellent wound repair dressing.Above-mentioned purpose that the invention is realized by the following technical scheme.
1. a kind of wound repair dressing is porous material, is characterized in that, surface is attached with the collagen of Porcine HGF Albumen.Manufacturing method includes the following steps:
(1) three-dimensional fiber sill is manufactured
Step 1: Biodegradable fibers are dispersed in water or ethyl alcohol, homogeneous suspension is formed;In the suspension, The mass fraction of fiber is 1-10%;Step 2: the suspension is carried out ripening 8-15h at 15-36 DEG C, make suspended Liquid forms coagulated mass;Step 3: removing the water or ethyl alcohol solidified in the coagulated mass using supercritical drying drying method, fiber is formed Staggeredly material;Step 4: the fiber material that interlocks is carried out 1-5h thermal crosslinking treatment, the three-dimensional that is adhesively fixed of fiber cross-point is obtained Fiber-based material;
Biodegradable fibers are selected from: polylactic acid, polycaprolactone, polyglycolide, polyurethane, polyvinyl alcohol or silk-fibroin, Fiber made of the one or more substances of peptide polymer, alginic acid of elastin mimicry.
(2) porous processing is carried out
The Dressing substrate dipping that step (1) is obtained in water, then adds and causes porous combination object, and treatment temperature 20~ 60 DEG C, the time is 10~60min.
The cause porous combination object are as follows: magnesium carbonate, foaming agent and biocompatible adhesive, wherein the foaming agent includes phosphorus Hydrochlorate and hydrophosphate, the phosphate and the hydrophosphate existing molar ratio in the composition are 1:3-1:15, the combination Reaction is when object is hydrated to generate the carbon dioxide as gas component, wherein releasing the gas component from the composition At least 8% porosity is generated in the composition;
(3) collagen is impregnated
Porous treated three-dimensional fiber sill is impregnated into the collagen hydrosol containing Porcine HGF, then Dry, Porcine HGF content is 1-10wt%, and the content of collagen is 130-1500IU/mL;
(4) crosslinking curing
Crosslinking curing is carried out after drying, wherein the crosslinking agent is selected from 1- ethyl -3- (3- DimethylAminopropyl) - Carbodiimides, glutaraldehyde, dialdehyde starch, glycol glycidyl ethers, propanetriol-diglycidyl-ether, myrica extract, wattle skin Any one of own diisocyanate of tannin extract, 1,6-;After crosslinking curing, wound repair dressing is obtained.
Wherein the content concn of crosslinking agent is preferably 0.01~0.05mol/L in the cross-linking agent solution, more preferably 0.03mol/L;The time of the crosslinking curing is preferably 5~12h, more preferably 8~9h.
The cell factor is the factor gone back to the nest or chemotactic or cell differentiation work to cell, these factors can be selected from Cell directional migration factor (SDF-1), epidermal growth factor (EGF), fibroblast growth factor (FGF), interleukin I L-3, Angiogenin binding factor (ECM), transforminggrowthfactor-α (TGF- α), platelet-derived growth factor (PDGF) or thin Born of the same parents' directional migration factor, insulin-like growth factor, bone morphogenetic protein, bone morphogenesis protein-2, vascular endothelial growth factor Son, Connective Tissue Growth Factor, basic fibroblast growth factor, osteopontin, growth hormone (such as: somatotropin) Equal cytotaxis and adhesion factor
In the biocompatible adhesive further include: nucleic acid, carbohydrate, protein, polypeptide is poly- ('alpha '-hydroxy acids), Poly- (lactone), it is poly- (amino acid), it is poly- (acid anhydrides), it is poly- (ortho esters), it is poly- (acid anhydrides-CO- acid imide), it is poly- (orthocarbonic ester), gather (Alpha-hydroxy alkanoic acid ester), poly- (phosphate), poly- (L- lactide) (PLLA), poly(D,L-lactide) (PDLLA), polyglycolide (PGA), poly- (lactide-CO- glycolide) (PLGA), poly- (L- lactide-CO-D, L- lactide), poly- (D, L- lactide- CO- propylene carbonate), poly butyric ester (PHB), polycarboxylic acids is poly- (hydrochloric acid allylamine), poly- (chlorination diallyl dimethyl Ammonium), poly- (ethylenimine), poly- fumaric acid propylene glycol ester, polyvinyl alcohol, polyvinylpyrrolidone, polyethylene, poly- methyl Methyl acrylate, carbon fiber, polyethylene glycol, poly(ethylene oxide)polymers are poly- (vinyl alcohol), poly(vinyl pyrrolidone), epoxy second Alkane-CO- propylene oxide block copolymer, poly- (ethylene glycol terephthalate), polyamide and their copolymer.
The biocompatible adhesive is selected from: alginic acid, arabic acid, guar gum, xanthan gum, gelatin, chitin, takes off second Acyl chitin, acetic acid chitosan, lactic acid chitosan, chondroitin sulfate, N, the deacetylated shell of O- carboxymethyl are more Sugar, glucan, Fibrin Glue, glycerol, hyaluronic acid, Sodium Hyaluronate, cellulose, aminoglucose, proteoglycans, starch, cream Acid, ethylene oxide and propylene oxide copolymers, sodium glycero-phosphate, collagen, glycogen, keratin, silk and their mixture.
Compared with prior art, the invention has the following beneficial effects:
(1) so that dressing has higher and more evenly hole than conventional wound-surface plaster, enhancing is applied for the introducing of pore composition The gas permeability of material in use;
(2) manufacturing method of three-dimensional fiber base is more simple relative to the electrostatic spinning technique of traditional surface of a wound film, is easy control System, no matter raw material or process costs it is all more cheap, with preferable breathable moisture permeability;
(3) Wound dressing produced by the present invention can promote dermal fibroblasts to grow, and accelerate the healing of damage skin, For hospital gauze, the required days minus that animal skin heals completely is a half left and right, and is not in the surface of a wound Red and swollen and cicatricial contracture.
Specific embodiment
Embodiment 1:
(1) three-dimensional fiber sill is manufactured
Step 1: vinal is dispersed in water, homogeneous suspension is formed;In the suspension, the matter of fiber Measuring score is 7%;Step 2: the suspension is carried out ripening 8h at 15 DEG C, suspension is made to form coagulated mass;Third Step: removing the water or ethyl alcohol solidified in the coagulated mass using supercritical drying drying method, forms fiber and interlocks material;Step 4: The fiber material that interlocks is subjected to 5h thermal crosslinking treatment, obtains the three-dimensional fiber sill that is adhesively fixed of fiber cross-point;
(2) porous processing is carried out
The three-dimensional fiber sill dipping that step (1) is obtained in water, then adds and causes porous combination object, processing temperature 25 DEG C of degree, time 18min.
The cause porous combination object are as follows: magnesium carbonate, foaming agent and biocompatible adhesive, wherein the foaming agent includes phosphorus Hydrochlorate and hydrophosphate, the phosphate and the hydrophosphate existing molar ratio in the composition are 1:7, the composition hydration Shi Fanying is combining to generate the carbon dioxide as gas component wherein releasing the gas component from the composition At least 8% porosity is generated in object;
(3) collagen is impregnated
Porous treated three-dimensional fiber sill is impregnated into the collagen hydrosol containing Porcine HGF, then Dry, Porcine HGF content is 5wt%, and the content of collagen is 1300IU/mL;
(4) crosslinking curing
Crosslinking curing is carried out after drying, wherein the crosslinking agent is glycol glycidyl ethers, and crosslinking curing terminates Afterwards, wound repair dressing is obtained.
Embodiment 2:
(1) three-dimensional fiber sill is manufactured
Step 1: wire protein fiber is dispersed in water or ethyl alcohol, homogeneous suspension is formed;In the suspension, fiber Mass fraction be 7%;Step 2: the suspension is carried out ripening 8h at 15 DEG C, suspension is made to form coagulated mass; Step 3: remove the water or ethyl alcohol solidified in the coagulated mass using supercritical drying drying method, forms fiber and interlock material;4th Step: the fiber material that interlocks is subjected to 2h thermal crosslinking treatment, obtains the three-dimensional fiber sill that is adhesively fixed of fiber cross-point;
(2) porous processing is carried out
The three-dimensional fiber sill dipping that step (1) is obtained in water, then adds and causes porous combination object, processing temperature 20 DEG C of degree, time 50min.
The cause porous combination object are as follows: magnesium carbonate, foaming agent and biocompatible adhesive, wherein the foaming agent includes phosphorus Hydrochlorate and hydrophosphate, the phosphate and the hydrophosphate existing molar ratio in the composition are 1:6, the composition hydration Shi Fanying is combining to generate the carbon dioxide as gas component wherein releasing the gas component from the composition At least 8% porosity is generated in object;
(3) collagen is impregnated
Porous treated three-dimensional fiber sill is impregnated into the collagen containing basic fibroblast growth factor Then the hydrosol is dried, basic fibroblast growth factor content is 8wt%, and the content of collagen is 130IU/mL;
(4) crosslinking curing
Crosslinking curing is carried out after drying, wherein the crosslinking agent is dialdehyde starch, after crosslinking curing, is obtained Wound repair dressing.Wherein the content concn of crosslinking agent is 0.03mol/L in the cross-linking agent solution;The crosslinking curing Time is 8~9h.
Comparative example 1:
1) RGD recombinant spider silk protein-polyvinyl alcohol composite fiber film is prepared
RGD recombinant spider silk protein (Ji'nan University's offer) and polyvinyl alcohol (average degree of polymerization is 2400~2500) are dissolved in In the formic acid solution of 98wt%, it is configured to the spinning solution containing 5wt%RGD recombinant spider silk protein and 5wt% polyvinyl alcohol.Spinning In the syringe of silk liquid sucking 2mL specification, using electrospinning technology, 80kV (voltage strength), 20cm (syringe needle away from Collect screen surfaces), 5ml/h (spinning solution flow), under the conditions of 45 DEG C, spinning solution is prepared into RGD recombinant spider silk protein-polyethylene Alcohol composite cellulosic membrane.
2) bFGF- collagen solution is prepared
Collagen (offer of Shijiazhuang Xu Er U.S. Biotechnology Co., Ltd) is dissolved in sterile water and is configured to 2wt%'s Collagen solution adds bFGF (offer of Beijing Ke Xin Biotechnology Co., Ltd) by 500IU/ml, obtains bFGF- collagen egg White solution.
3) wound repair dressing is prepared
RGD recombinant spider silk protein obtained above -37 DEG C of polyvinyl alcohol composite fiber film constant temperature is immersed in above-mentioned be made BFGF- collagen solution in 30min, be then placed in room temperature nature gel drying 2h in gel mold, obtain drying and moulding Composite cellulosic membrane.
The composite cellulosic membrane of drying and moulding is put into the EDCHCl solution that concentration is 0.01~0.05mol/L and is crosslinked 8h It reinforces, obtains the wound repair dressing with a thickness of 0.05mm.
Wound repair dressing obtained is finally put into aseptic package bag, carries out ethylene oxide sterilizing.
Comparative example 2:
Without step (2) porous processing, other steps while embodiment 1
Comparative example 3:
(1) three-dimensional fiber sill is manufactured
Step 1: polylactic acid is dispersed in water or ethyl alcohol, homogeneous suspension is formed;In the suspension, the matter of fiber Measuring score is 13%;Step 2: the suspension is carried out ripening 20h at 40 DEG C, suspension is made to form coagulated mass;The Three steps: removing the water or ethyl alcohol solidified in the coagulated mass using supercritical drying drying method, forms fiber and interlocks material;4th Step: the fiber material that interlocks is subjected to 6h thermal crosslinking treatment, obtains the three-dimensional fiber sill that is adhesively fixed of fiber cross-point;
(2) porous processing is carried out
The three-dimensional fiber sill dipping that step (1) is obtained in water, then adds and causes porous combination object, processing temperature 15 DEG C of degree, time 9min.
The cause porous combination object are as follows: magnesium carbonate, foaming agent and biocompatible adhesive, wherein the foaming agent includes phosphorus Hydrochlorate and hydrophosphate, the phosphate and the hydrophosphate existing molar ratio in the composition are 1:16;
(3) collagen is impregnated
Porous treated three-dimensional fiber sill is impregnated into the collagen hydrosol containing Porcine HGF, then Dry, Porcine HGF content is 15wt%, and the content of collagen is 100IU/mL;
(4) crosslinking curing
Crosslinking curing is carried out after drying, wherein the crosslinking agent is selected from 1- ethyl -3- (3- DimethylAminopropyl) - Carbodiimides after crosslinking curing, obtains wound repair dressing.Wherein the content of crosslinking agent is dense in the cross-linking agent solution Degree is preferably 0.08mol/L, the time 14h of the crosslinking curing.
Test of the wound repair dressing in the surface of a wound
It is tested with 100 white rabbits, establishes wounds in animals model, be randomly divided into 5 groups: example 1 group, 2 groups of embodiment, reality Apply 3 groups of example, comparative example group and blank control group, every group 20.After white rabbit anesthesia disinfection, the notch at 3cm × 3cm is manufactured, it is complete Whole removal skin holostrome, respectively with the embodiment group and comparative example group film patch flap coverage with surface of a wound same size, blank control The surface of a wound does not do specially treated, and then sterile pressurized is wrapped up.Postoperative intramuscular injection penicillin 10u/kgbw is injected for three days on end 2 times a day, Prevention infection.Dressing weekly, removal each group film are pasted, are wrapped up after wound clean by original method.Groups of animals wound is observed after 1 to 4 week The variation in face calculates Wound healing rate, Wound healing rate=(original surface of a wound area-existing surface of a wound area)/original surface of a wound area × 100%, as a result such as the following table 1:
The Wound healing rate (%) of the postoperative different time points each group of table 1
Group First week Second week 4th week
Blank control 14.91 63.33 98.94
Comparative example 1 23.76 83.58 99.97
Comparative example 2 25 79 98.88
Comparative example 3 20 81 98.90
Embodiment 1 27 90 99.99
Embodiment 2 29 89 99.97
Table 1 shows that second week healing rate of the invention is apparently higher than the wound repair dressing of other methods manufacture.Embodiment The group surface of a wound has no clear scar contracture, oedema and inflammation occurs without red and swollen and inflammation, blank control group, and comparative example part has obviously Cicatricial contracture.
The measurement of porosity: under constant temperature conditions, dehydrated alcohol is filled into 5ml specific gravity bottle, weighed (W1), by compound fibre Tie up film weighing (Ws).And film is placed in specific gravity bottle, 15min is stood, is de-gassed using vacuum pump, until bubble-free escapes, It is diffused into ethyl alcohol sufficiently in the hole of film, fills it up with ethyl alcohol, weigh (W2).The sample for being saturated with ethyl alcohol is taken out, to remaining second Alcohol and specific gravity bottle are weighed (W3).Counting Formula: porosity=(W2-W3-Ws)/(W1-W3)
Table 2
Porosity (%)
Embodiment 1 88%
Embodiment 2 86%
Comparative example 1 82%
Comparative example 2 65%
Comparative example 3 83%

Claims (1)

1. a kind of wound repair dressing is porous material, is characterized in that, surface is attached with the collagen of Porcine HGF; Its manufacturing method includes the following steps:
(1) three-dimensional fiber sill is manufactured
Step 1: Biodegradable fibers are dispersed in water or ethyl alcohol, homogeneous suspension is formed;In the suspension, fiber Mass fraction be 1-10%;Step 2: the suspension is carried out ripening 8-15h at 15-36 DEG C, make suspension shape At coagulated mass;Step 3: removing the water or ethyl alcohol solidified in the coagulated mass using supercritical drying drying method, forms fiber and interlock Material;Step 4: the fiber material that interlocks is carried out 1-5h thermal crosslinking treatment, the three-dimensional fiber that is adhesively fixed of fiber cross-point is obtained Sill;
Biodegradable fibers are selected from: polylactic acid, polycaprolactone, polyglycolide, polyurethane, polyvinyl alcohol or silk-fibroin, elastic force Fiber made of the one or more substances of peptide polymer, alginic acid of albumen mimicry;
(2) porous processing is carried out
The three-dimensional fiber sill dipping that step (1) is obtained in water, then adds and causes porous combination object, treatment temperature 20 ~60 DEG C, the time is 10~60min;
The cause porous combination object are as follows: magnesium carbonate, foaming agent and biocompatible adhesive, wherein the foaming agent includes phosphate And hydrophosphate, the phosphate and hydrophosphate existing molar ratio in the composition are 1:3-1:15, the composition water It reacts to generate the carbon dioxide as gas component when conjunction, wherein releasing the gas component in group from the composition At least 8% porosity is generated in conjunction object;
(3) collagen is impregnated
Porous treated three-dimensional fiber sill is impregnated into the collagen hydrosol containing Porcine HGF, is then done Dry, Porcine HGF content is 1-10wt%, and the content of collagen is 130-1500IU/mL;
(4) crosslinking curing
Crosslinking curing is carried out after drying, wherein it is sub- that crosslinking agent is selected from 1- ethyl -3- (3- DimethylAminopropyl)-carbonization two Amine, glutaraldehyde, dialdehyde starch, glycol glycidyl ethers, propanetriol-diglycidyl-ether, myrica extract, wattle extract, 1,6- Any one of own diisocyanate;After crosslinking curing, wound repair dressing is obtained.
CN201610665179.1A 2016-08-14 2016-08-14 A kind of wound repair dressing Active CN106267315B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610665179.1A CN106267315B (en) 2016-08-14 2016-08-14 A kind of wound repair dressing

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610665179.1A CN106267315B (en) 2016-08-14 2016-08-14 A kind of wound repair dressing

Publications (2)

Publication Number Publication Date
CN106267315A CN106267315A (en) 2017-01-04
CN106267315B true CN106267315B (en) 2019-07-23

Family

ID=57670497

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610665179.1A Active CN106267315B (en) 2016-08-14 2016-08-14 A kind of wound repair dressing

Country Status (1)

Country Link
CN (1) CN106267315B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107913434A (en) * 2017-11-21 2018-04-17 深圳大学 A kind of preparation method of aerogel dressing
CN109966549B (en) * 2017-12-28 2021-12-31 北京纳通科技集团有限公司 Three-dimensional bionic bone repair material and preparation method thereof
CN108939128A (en) * 2018-06-05 2018-12-07 吉林康众新材料科技有限公司 With medicament slow release and from the function and service dressing and preparation method thereof of antibacterial effect
CN108926733A (en) * 2018-07-03 2018-12-04 昆明理工大学 A kind of preparation method of medical VSD dressing
CN109289082A (en) * 2018-11-22 2019-02-01 李忠 A kind of absorbability medical hemostatic bibre material and preparation method thereof
CN110755676B (en) * 2019-10-21 2021-06-15 浙江大学 Composite dressing for promoting wound healing and regeneration and loading traditional Chinese medicine exosomes and preparation method thereof
CN111588901A (en) * 2020-05-28 2020-08-28 中怡(深圳)医疗科技集团有限公司 Self-assembled nanofiber dressing for promoting diabetic ulcer vascularization repair, preparation method and application
CN111870732B (en) * 2020-07-20 2022-06-14 卓阮医疗科技(苏州)有限公司 Hemostatic particles capable of inducing tissue regeneration and repair and preparation method and application thereof
CN114272434A (en) * 2021-03-16 2022-04-05 卫纳塞德(北京)医疗科技有限公司 Degradable medical cold compress hydrogel and preparation method thereof
CN113274954B (en) * 2021-07-21 2021-11-02 北京德人健康科技有限公司 Microsphere emulsification technology
CN115845126A (en) * 2022-12-26 2023-03-28 深圳钧兴生物科技有限公司 Bionic collagen liquid dressing and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103285424A (en) * 2013-05-27 2013-09-11 东华大学 Three-dimensional fiber-based aerogel tissue engineering scaffold and preparation method thereof
CN105088779A (en) * 2015-08-05 2015-11-25 广州赛莱拉生物基因工程有限公司 Collagen attachment membrane and preparation method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103285424A (en) * 2013-05-27 2013-09-11 东华大学 Three-dimensional fiber-based aerogel tissue engineering scaffold and preparation method thereof
CN105088779A (en) * 2015-08-05 2015-11-25 广州赛莱拉生物基因工程有限公司 Collagen attachment membrane and preparation method thereof

Also Published As

Publication number Publication date
CN106267315A (en) 2017-01-04

Similar Documents

Publication Publication Date Title
CN106267315B (en) A kind of wound repair dressing
Pei et al. Effectively promoting wound healing with cellulose/gelatin sponges constructed directly from a cellulose solution
CN106178063B (en) A kind of no immunological rejection adhesive bandage
US11511018B2 (en) Conductive biomimetic skin scaffold material with self-repairing function and a method of preparing the same
Teixeira et al. Recent advances in fiber–hydrogel composites for wound healing and drug delivery systems
WO2014058100A1 (en) Cell-containing, biocompatible polymer-natural biocompatible material hybrid scaffold and fabrication method therefor
CN104857569A (en) Preparation method of fibroin and graphene oxide composite bracket material
CN112675360B (en) Preparation and application of hADSCs-loaded double-layer skin bionic hydrogel composite scaffold
Xie et al. Adult stem cells seeded on electrospinning silk fibroin nanofiberous scaffold enhance wound repair and regeneration
US11529226B2 (en) Artificial skin and a preparation method thereof
Hu et al. In-situ formable dextran/chitosan-based hydrogels functionalized with collagen and EGF for diabetic wounds healing
CN102228695A (en) Method for preparing basic fibroblast growth factor sustained-release carrier
CN113289050B (en) Hemostatic sponge and preparation method thereof
CN109381732A (en) Electrostatic spinning dressing, preparation method and the application of growth factor-loaded micromolecular inhibitor
KR102473363B1 (en) Spray type hydrogel wound coating preparation method and Spray type hydrogel wound coating thereof
CN109731130A (en) A kind of method that low-temperature biological 3D printing technique prepares hydrogel Wound dressing
CN114225113B (en) Degradable artificial dura mater with double-layer structure and preparation method thereof
Yaşayan et al. Natural polymers for wound dressing applications
Zhong et al. Investigation on repairing diabetic foot ulcer based on 3D bio-printing Gel/dECM/Qcs composite scaffolds
CN106667986B (en) Rhein/aquagel and its preparation method and application
CN108478852A (en) A kind of pharmaceutical products, the carrier for loading pharmaceutical products, hydrogel and its method
CN116392578A (en) Collagen-containing wound repair combined preparation and preparation process thereof
Rijal et al. Biomaterials for diabetic wound-healing therapies
CN109602953A (en) A kind of New-type long-acting sustained release VEGF and bFGF degradable biological nanometer diaphragm and preparation method thereof
CN112891610A (en) Pig-derived fibrin-electrostatic spinning nanofiber antibacterial hemostatic patch and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Zhu Kunfu

Inventor after: Zhu Lei

Inventor after: Zhao Zhongjun

Inventor after: Zhang Tianqi

Inventor before: Zhang Tianqi

CB03 Change of inventor or designer information
TA01 Transfer of patent application right

Effective date of registration: 20190612

Address after: 274300 Fanlou Road South, Shanxian Development Zone, Heze City, Shandong Province

Applicant after: SHANDONG ZHUSHI PHARMACEUTICAL GROUP CO., LTD.

Address before: 246702 Zongyang City, Tongling, Anhui province Yingbin Avenue Liancheng Lake Bridge, 502, room 14, Dragon City, north.

Applicant before: Zhang Tianqi

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant